Sana Biotechnology
SANA
88 hedge funds and large institutions have $2.48B invested in Sana Biotechnology in 2021 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 36 increasing their positions, 17 reducing their positions, and 9 closing their positions.
5,015% more call options, than puts
Call options by funds: $15.5M | Put options by funds: $303K
112% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 17
89% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 9
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
28% more capital invested
Capital invested by funds: $1.93B → $2.48B (+$545M)
10% more funds holding
Funds holding: 80 → 88 (+8)
6.15% more ownership
Funds ownership: 52.38% → 58.53% (+6.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$108M |
| 2 |
BlackRock
New York
|
+$68.9M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$20.8M |
| 4 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
+$14.6M |
| 5 |
State Street
Boston,
Massachusetts
|
+$14.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$16.3M |
| 2 |
SM
SB Management
Abu Dhabi,
United Arab Emirates
|
-$8.74M |
| 3 |
Public Sector Pension Investment Board (PSP Investments)
Montreal,
Quebec, Canada
|
-$7.91M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.02M |
| 5 |
Citigroup
New York
|
-$2.01M |
SANA Hedge Fund Activity: Q3 2021 in Review
88 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Sana Biotechnology (SANA) for Q3 2021, worth a combined $2.48B — up 28% from $1.93B a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new SANA positions and 9 closed out — a net gain of 8 holders — while 36 added to existing stakes and 17 trimmed.
The largest buyer was Vanguard Group, adding an estimated $108M. The largest seller was Wellington Management Group, exiting entirely with an estimated $16.3M sold.
- 88 institutional investors held Sana Biotechnology (SANA) as of Q3 2021, up from 80 in Q2 2021.
- Funds reported $2.48B of Sana Biotechnology stock for Q3 2021, up 28% quarter-over-quarter.
- 17 funds opened new Sana Biotechnology positions in Q3 2021 and 9 closed out, a net change of +8 holders.
- The largest Sana Biotechnology buyer in Q3 2021 was Vanguard Group, an estimated $108M added.
- The largest Sana Biotechnology seller in Q3 2021 was Wellington Management Group, an estimated $16.3M sold.
Based on aggregated 13F filings for Q3 2021.